New research indicates that individuals who stop using blockbuster slimming jabs like semaglutide or tirzepatide can put back on reduced body mass much more quickly than those who halt conventional lifestyle regimens.
Research printed in a leading medical journal points out that while overweight individuals can lose about a fifth of their total mass while undergoing treatment, the weight comes back at an estimated rate of 0.8 kg per month after stopping.
"Individuals using such drugs need to be informed of the risk of rapid weight regain when the therapy is stopped," warns expert Dr. Susan Jebb.
This pace of regain suggests a return to pre-treatment mass within about one and a half years.
Analyzing Approaches
The study, which looked at dozens of trials involving thousands of patients, contrasted the outcomes of the injectable medications with other pills.
Researchers note that people who lose weight through lifestyle changes alone typically have a less rapid creep back—approximately 100 grams monthly—after stopping.
Explaining the Rapid Regain
Nutrition scientists suggest the way of the injections accounts for the amplified rebound.
The injections copy a body's own chemical called glucagon-like peptide-1, which controls appetite.
"Artificially providing the hormone concentrations several times higher than the body's typical production might result in the system to generate a reduced amount of its endogenous hormone, and could diminish responsiveness to its effects," said Dr. Adam Collins, a nutrition specialist.
"Stopping of this GLP-1 'fix' results in appetite is no longer kept in check, making overeating much more probable."
A Chronic Condition?
Medical guidelines advise the injections for people with weight-linked medical conditions, alongside recommended diet and exercise modifications.
Many experts argue that, due to the high risk of weight regain, the therapy should be considered life-long.
This opinion is reinforced by pharmaceutical companies, who say that the results "highlight the chronic character of excess weight," similar to managing diseases like hypertension.
Patient Experiences
Users who have come off the medication report a intense return of cravings.
"I experienced a trigger that goes on and you become ravenous," recalled an individual.
This challenge is worsened if patients have not established permanent lifestyle or habit changes during treatment.
Significant Use
Figures show that millions of adults in the UK have used weight-loss jabs in the past year, with demand being substantial.
- Use is greater among females than males.
- The middle-aged age group shows the greatest level of interest.
- A large proportion obtain the drugs through private prescriptions rather than the NHS.
Finally, experts emphasize that while GLP-1 drugs are effective tools for shedding pounds, they are not a permanent cure and maintained weight loss relies on ongoing lifestyle changes.
